Suppr超能文献

新型转基因水稻疫苗。

Novel transgenic rice-based vaccines.

作者信息

Azegami Tatsuhiko, Itoh Hiroshi, Kiyono Hiroshi, Yuki Yoshikazu

机构信息

Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.

出版信息

Arch Immunol Ther Exp (Warsz). 2015 Apr;63(2):87-99. doi: 10.1007/s00005-014-0303-0. Epub 2014 Jul 16.

Abstract

Oral vaccination can induce both systemic and mucosal antigen-specific immune responses. To control rampant mucosal infectious diseases, the development of new effective oral vaccines is needed. Plant-based vaccines are new candidates for oral vaccines, and have some advantages over the traditional vaccines in cost, safety, and scalability. Rice seeds are attractive for vaccine production because of their stability and resistance to digestion in the stomach. The efficacy of some rice-based vaccines for infectious, autoimmune, and other diseases has been already demonstrated in animal models. We reported the efficacy in mice, safety, and stability of a rice-based cholera toxin B subunit vaccine called MucoRice-CTB. To advance MucoRice-CTB for use in humans, we also examined its efficacy and safety in primates. The potential of transgenic rice production as a new mucosal vaccine delivery system is reviewed from the perspective of future development of effective oral vaccines.

摘要

口服疫苗可诱导全身和黏膜抗原特异性免疫反应。为控制猖獗的黏膜传染病,需要研发新的有效口服疫苗。植物源疫苗是口服疫苗的新候选者,在成本、安全性和可扩展性方面比传统疫苗具有一些优势。水稻种子因其稳定性和在胃中的抗消化性而适合用于疫苗生产。一些基于水稻的疫苗对感染性、自身免疫性和其他疾病的疗效已在动物模型中得到证实。我们报道了一种名为MucoRice-CTB的基于水稻的霍乱毒素B亚基疫苗在小鼠中的疗效、安全性和稳定性。为了推进MucoRice-CTB用于人类,我们还在灵长类动物中检测了其疗效和安全性。从有效口服疫苗未来发展的角度,对转基因水稻生产作为一种新的黏膜疫苗递送系统的潜力进行了综述。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验